CVS Health Co. (NYSE:CVS) Shares Bought by Coston McIsaac & Partners

Coston McIsaac & Partners grew its holdings in shares of CVS Health Co. (NYSE:CVS) by 34.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 724 shares of the pharmacy operator’s stock after purchasing an additional 185 shares during the period. Coston McIsaac & Partners’ holdings in CVS Health were worth $57,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. Atticus Wealth Management LLC boosted its stake in shares of CVS Health by 149.0% during the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 219 shares in the last quarter. USA Financial Formulas boosted its stake in shares of CVS Health by 573.2% during the 4th quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock worth $30,000 after acquiring an additional 321 shares in the last quarter. Ables Iannone Moore & Associates Inc. purchased a new stake in shares of CVS Health during the 4th quarter worth approximately $32,000. Creekmur Asset Management LLC purchased a new stake in shares of CVS Health during the 4th quarter worth approximately $34,000. Finally, Steph & Co. boosted its stake in shares of CVS Health by 192.0% during the 1st quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock worth $35,000 after acquiring an additional 288 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 1.2 %

NYSE CVS traded up $0.70 during trading hours on Friday, hitting $59.06. The company had a trading volume of 14,343,538 shares, compared to its average volume of 11,322,786. CVS Health Co. has a fifty-two week low of $52.77 and a fifty-two week high of $83.25. The company has a market capitalization of $74.14 billion, a price-to-earnings ratio of 10.38, a P/E/G ratio of 0.56 and a beta of 0.53. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. The firm’s 50 day moving average is $59.56 and its 200 day moving average is $70.17.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). The company had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.20 earnings per share. Sell-side analysts anticipate that CVS Health Co. will post 7.02 earnings per share for the current fiscal year.

Insider Activity

In other CVS Health news, Director Edward J. Ludwig bought 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The stock was bought at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the purchase, the director now directly owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

CVS has been the topic of a number of recent research reports. UBS Group lowered CVS Health from a “buy” rating to a “neutral” rating and reduced their target price for the company from $85.00 to $60.00 in a research note on Thursday, May 2nd. Robert W. Baird initiated coverage on CVS Health in a research note on Thursday, May 30th. They issued a “neutral” rating and a $61.00 target price on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $58.00 target price on shares of CVS Health in a research note on Wednesday, June 12th. Baird R W raised CVS Health to a “hold” rating in a research note on Thursday, May 30th. Finally, Truist Financial reissued a “buy” rating and set a $66.00 price target (down previously from $90.00) on shares of CVS Health in a research note on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.